BioSpaceOriginal article
Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer
Phase 2positiveINBRX-106KeytrudaPositive
AI Analysis
Summary
Inhibrx announced positive Phase 2 results showing INBRX-106, an OX40 agonist add-on to Keytruda, outperformed Keytruda monotherapy in head and neck cancer patients, with particularly strong performance in HPV-positive disease.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
INBRX-106 as OX40 agonist add-on demonstrated superior efficacy compared to Keytruda alone in head and neck cancer, particularly in HPV-positive disease
Importance:7/10
Sentiment:
0.85
oncologyimmunotherapyhead and neck cancerHPV-positivePhase 2positive dataOX40 agonist
Related Companies
Read the original article
Published by BioSpace on September 8, 2026 2:50 PM